SubQ vs IM Testosterone Injections: Which Is Better for TRT?

For decades, testosterone replacement therapy meant one thing: intramuscular injection. A 1–1.5 inch needle, once or twice per week, deep into the glute or quadricep. It works. The research behind it is solid. But it's not the only option.

Subcutaneous (SubQ) testosterone injections — delivered into the fat layer just below the skin — have gained significant traction among TRT patients and forward-thinking physicians. The appeal is straightforward: smaller needles, less pain, more injection sites, and emerging evidence that SubQ may produce more stable hormone levels with lower peaks.

This guide covers the head-to-head comparison: absorption, hormone stability, hematocrit impact, estrogen, pain, and patient preference.

How SubQ and IM Injections Differ

Intramuscular (IM): - Injection depth: 1–1.5 inches into muscle (glute, quad, delt) - Needle: typically 23–25 gauge, 1–1.5 inch - Absorption: fast — directly into muscle vasculature - Peak: higher testosterone peak 24–48 hours post-injection - Common sites: ventroglute, dorsoglute, vastus lateralis (quad), deltoid

Subcutaneous (SubQ): - Injection depth: 5/16–1/2 inch into fat layer - Needle: 28–31 gauge (insulin-style), 1/2 inch or shorter - Absorption: slower — through the subcutaneous lymphatic and capillary network - Peak: more blunted, more gradual curve - Common sites: abdomen, love handles, upper outer thigh, upper buttock fat

The slower absorption of SubQ is actually a benefit for many patients: the testosterone level curve is flatter, reducing the peak-to-trough swings that cause mood and energy fluctuations between injections.

What the Research Shows

Several key studies have compared SubQ and IM testosterone:

A 2017 study in the Journal of Clinical Endocrinology & Metabolism found that SubQ testosterone cypionate achieved equivalent serum testosterone levels to IM in men with hypogonadism, with similar free testosterone and bioavailable testosterone concentrations.

A 2020 study in Urology observed that men on SubQ testosterone had lower hematocrit increases compared to IM, a meaningful clinical benefit given that polycythemia (high red blood cell count) is one of the main reasons TRT is paused or discontinued.

Patient experience surveys consistently show higher satisfaction with SubQ due to reduced injection pain and anxiety, particularly among patients new to self-injection.

The clinical consensus: SubQ is an acceptable, effective alternative to IM with potentially favorable side effect profile in some patients.

Hormone Stability: The SubQ Advantage

One of the most cited reasons experienced TRT patients prefer SubQ is hormone stability. With intramuscular injection (especially with less-frequent dosing like once weekly), testosterone peaks sharply in the 24–48 hours post-injection, then declines toward trough by day 6–7.

This creates a cyclical "rollercoaster" some patients describe as energy and mood that vary with where they are in the injection cycle — feeling great days 1–3, gradually declining by day 6–7.

SubQ absorption is slower and more sustained. The peak is lower, the trough is higher, and the overall curve is flatter. For patients who inject twice weekly or more, this difference diminishes, but for once-weekly protocols, SubQ can meaningfully smooth the hormonal cycle.

Hematocrit: A Key Clinical Consideration

Polycythemia — an excessive rise in red blood cell count (measured as hematocrit) — is one of the most common side effects of TRT and the most common reason for dose reduction or protocol adjustment. Hematocrit above 52–54% is typically flagged as a concern.

The 2020 data suggesting lower hematocrit elevation with SubQ vs. IM is clinically significant. The proposed mechanism: the slower, more sustained absorption from SubQ maintains more steady-state testosterone with fewer acute peaks, which may reduce the erythropoietic (red blood cell production) stimulus that drives hematocrit increases.

If you have a history of elevated hematocrit on TRT, or if your hematocrit is trending upward, switching to SubQ and/or increasing injection frequency are both evidence-based adjustments to try before dose reduction.

Estrogen and Aromatization

Some clinicians and patients report lower estradiol on SubQ vs. IM, potentially because the blunted peak means less substrate for aromatization at any given moment. The evidence on this is not conclusive — studies are mixed — but it's a reasonable hypothesis based on pharmacokinetics.

What does appear to be consistent: men who switch to SubQ and increase injection frequency (e.g., moving from once-weekly IM to twice-weekly SubQ) often report better estrogen control without requiring aromatase inhibitor dosage changes.

Injection Technique: How to Do SubQ Correctly

1. Prepare your site: Clean with alcohol, let dry completely
2. Pinch or relax the fat: For leaner individuals, pinch the fat between thumb and forefinger. For more body fat, the tissue can lay flat.
3. Angle: 45–90 degrees depending on site and needle length. Most use 90 degrees with short needles.
4. Volume per site: Keep to 0.5mL or less per injection to minimize nodule formation
5. Sites: Rotate between abdomen (1–2 inches from navel), outer upper thigh fat, and love handles
6. Injection speed: Slow and steady — 10–15 seconds for 0.5mL reduces post-injection discomfort

Who Should Consider SubQ?

Strong candidates for SubQ: - Patients new to TRT who are needle-averse (much smaller gauge) - Men with elevated or trending hematocrit - Patients experiencing significant peak-trough mood/energy swings - Those who want to inject more frequently (daily or every other day) with less site fatigue - Patients with insufficient muscle mass for comfortable IM injection

IM remains reasonable for: - Patients already stable and happy on IM protocols - Individuals with very low body fat where SubQ fat depth is limited - Patients on protocols requiring larger volume per injection

The Bottom Line

SubQ testosterone is not a fringe approach — it's a legitimate, evidence-backed alternative to IM injection with practical advantages in pain, needle size, and potentially hematocrit and hormone stability. The research supports equivalent efficacy.

The best injection route is the one you'll do consistently. For many patients, that turns out to be SubQ — especially when they realize it requires a needle smaller than what they'd use to draw blood.

Marrow's physicians discuss injection options during onboarding and can adjust protocols based on your preference, lifestyle, and lab results. There's no single right answer — just what works best for you.